ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1632090
This article is part of the Research TopicE3 Ubiquitin Ligases: Critical Roles in Cancer Progression and Therapeutic ImplicationsView all articles
Comprehensive analysis based on the ubiquitination-and deubiquitylation-related genes reveals the function of NEURL3 in esophageal squamous cell carcinoma
Provisionally accepted
- Cancer Hospital, College of Medicine, Shantou University, Shantou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: As a highly invasive gastrointestinal malignancy, esophageal squamous cell carcinoma (ESCC) carries with its high morbidity and mortality. Accumulating evidence that abnormal activation of ubiquitination and deubiquitylation has been implicated in pathophysiology of ESCC. However, rare prognostic models for ubiquitination-related genes (URGs) and deubiquitylation-related genes (DRGs) have been built up in ESCC. Methods: From training dataset GSE53624, the differentially expressed prognostic URGs and DRGs were identified to develop a prognostic signature which was validated in GSE53622 and TCGA-ESCC dataset to show the robustness of the signature. The unsupervised clustering analysis was used to develop the molecular subtypes based on the prognostic URGs and DRGs to further confirm their prognosis value. Differences in terms of biological function, immune status, and drug sensitivity were evaluated between high- or low-risk groups. The nomogram was constructed by combining the URGs and DRGs prognostic signature and clinical characteristics to improve prediction efficacy. Loss-of-function studies were conducted to explore the biological function of NEURL3 in ESCC. Results: The URGs and DRGs prognostic signature consisted of 11 genes and exhibited high accuracy in predicting prognosis of ESCC patient. Based on these 11 URGs and DRGs, two molecular subtypes of ESCC (C1 and C2) were identified, with C2 subtype having significantly shorter OS than C1 subtype. The function enrichment analysis showed that these genes play key roles in essential processes such as tumor metastasis and immune response. Moreover, the risk score was closely related to infiltration abundance of some types of immune cell, gene markers of immune cells and immune checkpoint-related markers. The drug sensitivity analysis showed that dacomitinib and talazoparib may serve as anti-ESCC drugs through targeting MAPK14. The nomogram was established by combining the URGs and DRGs signature with age and TNM stage, and it also showed enhanced prognostic predictive accuracy. The in vitro experiments showed that knockdown of NEURL3 inhibited the proliferation and motility of ESCC cells. Conclusions: Based on the URGs and DRGs prognostic signature, a novel nomogram was constructed that could serve as a potentially reliable prognostic model and provide theoretical basis for uncovering potential therapeutic target in the treatment of ESCC.
Keywords: esophageal squamous cell carcinoma, Ubiquitination, deubiquitylation, nomogram, prognosis, immune microenvironment
Received: 20 May 2025; Accepted: 01 Aug 2025.
Copyright: © 2025 Lin, Li, Hong, Chen, Liu, Xu, Wu and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yu-Hui Peng, Cancer Hospital, College of Medicine, Shantou University, Shantou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.